Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 29.56M | 36.51M | 36.94M | 35.63M | 35.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.56M | 36.51M | 36.94M | 35.63M | 35.33M |
| Cost of Revenue | 47.66M | 46.05M | 47.16M | 31.53M | 30.50M |
| Gross Profit | -18.11M | -9.54M | -10.23M | 4.10M | 4.84M |
| SG&A Expenses | 30.53M | 37.47M | 45.26M | 50.14M | 50.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.19M | 83.51M | 92.43M | 81.67M | 80.99M |
| Operating Income | -48.63M | -47.01M | -55.49M | -46.04M | -45.66M |
| Income Before Tax | -54.23M | -52.85M | -55.62M | -46.27M | -46.18M |
| Income Tax Expenses | 829.00K | 1.21M | 1.57M | 1.21M | 433.00K |
| Earnings from Continuing Operations | -55.05 | -54.07 | -57.19 | -47.47 | -46.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.05M | -54.07M | -57.19M | -47.47M | -46.61M |
| EBIT | -48.63M | -47.01M | -55.49M | -46.04M | -45.66M |
| EBITDA | -48.53M | -46.85M | -55.27M | -45.77M | -45.33M |
| EPS Basic | -17.99 | -18.63 | -20.94 | -19.50 | -20.56 |
| Normalized Basic EPS | -10.01 | -10.32 | -12.72 | -11.90 | -12.75 |
| EPS Diluted | -17.99 | -18.63 | -20.94 | -19.50 | -20.56 |
| Normalized Diluted EPS | -10.01 | -10.32 | -12.72 | -11.90 | -12.75 |
| Average Basic Shares Outstanding | 12.27M | 11.57M | 10.72M | 9.83M | 9.12M |
| Average Diluted Shares Outstanding | 12.27M | 11.57M | 10.72M | 9.83M | 9.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |